Investigating targeted therapies for acute myeloid leukemia
Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies
This study is looking at how certain signals in immune cells can be used to create better treatments for acute myeloid leukemia (AML) and similar blood cancers, focusing on a protein called PI3K gamma to find new ways to help patients feel better with less harmful side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11015012 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific signaling pathways in myeloid cells can be targeted to improve treatments for acute myeloid leukemia (AML) and related blood cancers. By studying the PI3K gamma protein, which plays a crucial role in the development of these malignancies, the research aims to identify new therapeutic strategies that could lead to better patient outcomes. The approach involves analyzing the molecular mechanisms of AML and testing potential drugs that could selectively target these pathways, potentially leading to more effective and less toxic treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with acute myeloid leukemia or related myeloid malignancies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with myeloid malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for patients with acute myeloid leukemia, improving survival rates and quality of life.
How similar studies have performed: Other research has shown success in targeting specific proteins in different types of leukemia, suggesting that this approach may also be effective for acute myeloid leukemia.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Wood, Kris C. — Duke University
- Study coordinator: Wood, Kris C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.